UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant $oxtimes$ Filed by a Party other than the Registrant \Box						
Check th	appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to Section 240.14a-12					
	JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY					
	(Name of Registrant as Specified In Its Charter)					
	(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)					
Payment ⊠	f Filing Fee (Check the appropriate box): No fee required.					
	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.					
	 Title of each class of securities to which transaction applies: Aggregate number of securities to which transaction applies: Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): Proposed maximum aggregate value of transaction: Total fee paid: 					
	Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.					
	1) Amount Previously Paid: 2) Form, Schedule or Registration Statement No.: 3) Filing Party: 4) Date Filed:					

Your **Vote** Counts!

JAZZ PHARMACEUTICALS PLC

2021 Annual General Meeting Vote by July 28, 2021 11:59 PM ET

JAZZ PHARMACEUTICALS PLC FIFTH FLOOR, WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN 4, IRELAND ATTN: COMPANY SECRETARY



D55205-P55889

You invested in JAZZ PHARMACEUTICALS PLC and it's time to vote!

You have the right to vote on proposals being presented at the Annual General Meeting. THIS IS AN IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIAL FOR THE SHAREHOLDER MEETING TO BE HELD ON JULY 29, 2021.

Get informed before you vote

View the proxy statement, annual report and Irish statutory financial statements online at www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by requesting prior to July 15, 2021. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #



2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS Thursday, July 29, 2021 3:00 PM Local Time Jazz Pharmaceuticals plc Fifth Floor, Waterloo Exchange Waterloo Road Dublin 4, Ireland

During the meeting*: You may vote in person by attending the meeting.

Other voting options: You may also vote by Internet (by visiting www.ProxyVote.com or scanning the QR Barcode shown to the left), by phone (by calling 1-800-690-6903) or by mail (by requesting a paper copy of the proxy materials, which will include a proxy card with additional voting instructions). Vote by 11:59 P.M. ET on July 28, 2021. Have the control number indicated in this notice available when voting by Internet or by phone.

Smartphone users

Point your camera here and vote without entering a control number



^{*}Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

Vote at www.ProxyVote.com

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

You are receiving this communication because you held shares of Jazz Pharmaceuticals PLC as of June 2, 2021.

This communication presents only an overview of the more complete proxy materials, which contain important information and are available to you on the Internet or by mail.

We encourage you to access and review all of the important information contained in the proxy materials before voting. See the reverse side of this notice to obtain proxy materials and voting instructions.

1. To elect four nominees for director named below to hold office until the 2024 annual general meeting of shareholders. Nominees: 1a. Peter Gray 1b. Kenneth W. O'Keefe 1c. Mark D. Smith, M.D. 1d. Catherine A. Sohn, Pharm. D. 2. To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2021 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to determine KPMG's remuneration. 3. To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement. 4. To renew the Board of Director's existing authority under Irish law to allot and issue ordinary shares. 5. To renew the Board of Director's existing authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply. 6. To approve any motion to adjourn the annual meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the annual meeting to approve Proposal 5. NOTE: Such other business as may properly come before the meeting or any adjournment thereof.	Vo	ing Items		Board commends
1c. Mark D. Smith, M.D. 1d. Catherine A. Sohn, Pharm. D. 2. To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2021 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to determine KPMG's remuneration. 3. To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement. 4. To renew the Board of Director's existing authority under Irish law to allot and issue ordinary shares. 5. To renew the Board of Director's existing authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply. 6. To approve any motion to adjourn the annual meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the annual meeting to approve Proposal 5.	1. 1a.	shareholders. Nominees:	0	For
 1d. Catherine A. Sohn, Pharm. D. 2. To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2021 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to determine KPMG's remuneration. 3. To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement. 4. To renew the Board of Director's existing authority under Irish law to allot and issue ordinary shares. 5. To renew the Board of Director's existing authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply. 6. To approve any motion to adjourn the annual meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the annual meeting to approve Proposal 5. 	1b.	Kenneth W. O'Keefe	0	For
 To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2021 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to determine KPMG's remuneration. To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement. To renew the Board of Director's existing authority under Irish law to allot and issue ordinary shares. For or enew the Board of Director's existing authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply. To approve any motion to adjourn the annual meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the annual meeting to approve Proposal 5. 	1c.	Mark D. Smith, M.D.	0	For
Pharmaceuticals plc for the fiscal year ending December 31, 2021 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to determine KPMG's remuneration. 3. To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement. 4. To renew the Board of Director's existing authority under Irish law to allot and issue ordinary shares. 5. To renew the Board of Director's existing authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply. 6. To approve any motion to adjourn the annual meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the annual meeting to approve Proposal 5.	1d.	Catherine A. Sohn, Pharm. D.	0	For
officers as disclosed in the proxy statement. 4. To renew the Board of Director's existing authority under Irish law to allot and issue ordinary shares. 5. To renew the Board of Director's existing authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply. 6. To approve any motion to adjourn the annual meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the annual meeting to approve Proposal 5.	2.	Pharmaceuticals plc for the fiscal year ending December 31, 2021 and to authorize, in a binding vote, the board	0	For
 To renew the Board of Director's existing authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply. To approve any motion to adjourn the annual meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the annual meeting to approve Proposal 5. 	3.		0	For
without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply. 6. To approve any motion to adjourn the annual meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the annual meeting to approve Proposal 5.	4.	To renew the Board of Director's existing authority under Irish law to allot and issue ordinary shares.	0	For
solicit additional proxies if there are insufficient votes at the time of the annual meeting to approve Proposal 5.	5.	without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right	0	For
NOTE: Such other business as may properly come before the meeting or any adjournment thereof.	6.		0	For
	NO	TE: Such other business as may properly come before the meeting or any adjournment thereof.		

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Sign up for E-delivery".

D55206-P55889